Published On:November 23, 2016, 11:58 am
Allergy immunotherapy is also termed as allergy shots, is a prolonged treatment which lessens the symptoms for many people with allergic asthma, allergic rhinitis, conjunctivitis (eye allergy), or stinging insect allergy. These shots diminish the sensitivity towards allergens and frequently result in relief that lasts against the allergy symptoms even when the treatment is stopped. Therefore, it is the most cost-efficient, and beneficial approach for many people. Children as well as adults can receive the allergy immunotherapy, however it is not generally recommended for the children under age five. On the other side, when administering the allergy shots for an adult, health conditions such as cardiac disease must be considered and accordingly discussed with the immunologists. There are two types of immunotherapy - Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy. SCIT is an exclusive therapy for various allergic diseases due to its capability of rendering symptomatic relief at the same time altering disease by aiming at the underlying immunological mechanism. It has been successfully used in the treatment of rhinoconjunctivitis/ rhinitis, stinging insect hypersensitivity, and asthma in several clinical trials that are controlled. Immunotherapy addresses the reason for allergies by providing little doses of what a person is allergic to and this increases the immunity or tolerance level to the allergen and lessens the symptoms of allergies. Sublingual immunotherapy is rendered as drops under the tongue unlike the other injection immunotherapy.
The South East Asia Allergy Immunotherapies Market is predicted to experience prodigious growth and will possess a lucrative CAGR during the forecast period. Even though the accessible and existing therapies are greatly effective in alleviating, relieving and curbing the allergy symptoms, the market yet needs drugs which not just lessen inflammation but also avoid irreversible airway remodeling. Say for example, there are approximately 55% of diagnosed allergic rhinitis cases in the world. Moreover, asthma and allergic rhinitis are chronic diseases which cannot be treated completely; therefore most of these patients require prolonged treatment and lifestyles alterations. As a consequence, there exists an unmet medical need for new and enhanced targeted drugs to rectify and treat the underlying cause of such conditions, which will promote the market’s growth in the coming years. The allergy immunotherapies market is estimated to possess a lucrative outlook during the forecast period. Currently, the marketers are aiming allergens for Bermuda grass, birch pollen, mould, grass pollen, ragweed, etc.; nevertheless, numerous unknown agents can lead to allergic diseases, and determining the novel allergens will attribute towards the growth of this market in the near future.
To Request Sample Copy of This Report: http://www.qyresearchgroups.com/request-sample/163362
Region-wise the South East Asia Allergy Immunotherapies Market is segmented into regions such as Indonesia, Philippines, Thailand, Malaysia, Vietnam, and Singapore. The present market in this region is highly competitive and a few of its major key marketers are ALK-Abello, Stallergenes Greer, HAL, etc. the companies which manufacture and market superior safety and efficient drugs for the treatment of allergic rhinitis and asthma are predicted to garner a competitive benefit as compared to other companies.
We will be happy to help you find what you need. Please write to us: